Story
On June 10, 2026, Zhongguancun Development Group published a feature on Migrasome Therapeutics (Beijing) Co., Ltd., highlighting the company’s effort to translate original biological research into potential healthcare applications.
The article traces the journey from the discovery of the migrasome to the founding of the company. Professor Li Yu’s team at Tsinghua University has spent more than a decade studying migrasome biogenesis, physiological functions and links to disease. Migrasome Therapeutics was established in Beijing’s Changping Life Science Park in 2022 to advance this scientific foundation toward applications in diagnostics, cell therapy and drug delivery.
The feature also describes the long-term support provided by Zhongguancun Capital. The investor participated in the company’s early financing in 2023 and continued its support in 2024, while also helping connect the company with policy resources, industry networks and potential partners. The article presents the collaboration as an example of original science and patient capital working together to bridge the translational “valley of death.”
The report highlights the potential of migrasome biology in the early identification of coagulation-related disorders, as well as the company’s broader work in diagnostic testing, cell therapy and innovative drug-delivery systems. These programs remain at different stages of research and translation; future progress will be subject to the company’s formal disclosures and applicable regulatory information.
Migrasome Therapeutics will continue to begin with original biology, focus on real clinical needs, and work with hospitals, academic institutions, industry partners and investors to validate and translate migrasome technologies.